share_log

Johnson & Johnson | 424B2: Prospectus

Johnson & Johnson | 424B2: Prospectus

强生 | 424B2：募资说明书
美股sec公告 ·  05/15 16:36
Moomoo AI 已提取核心信息
Johnson & Johnson (JNJ.US), a leading healthcare company, has announced the issuance of a series of senior unsecured notes totaling $4 billion, with varying maturities and interest rates. The notes, due in 2029, 2031, 2034, and 2054, will pay interest semi-annually beginning December 1, 2024. The offering includes $1,150,000,000 of 4.800% notes due 2029, $1,150,000,000 of 4.900% notes due 2031, $850,000,000 of 4.950% notes due 2034, and $850,000,000 of 5.250% notes due 2054. The notes are senior unsecured obligations and will rank equally with other unsecured and unsubordinated debt. The company may redeem the notes at any time at specified redemption prices. The proceeds are intended for general corporate purposes, including the recently announced acquisition of Shockwave Medical, Inc., subject to customary closing conditions and regulatory approvals. The notes will be delivered through The Depository Trust Company on May 20, 2024, with J.P. Morgan, BofA Securities, and Citigroup acting as Joint Book-Running Managers.
Johnson & Johnson (JNJ.US), a leading healthcare company, has announced the issuance of a series of senior unsecured notes totaling $4 billion, with varying maturities and interest rates. The notes, due in 2029, 2031, 2034, and 2054, will pay interest semi-annually beginning December 1, 2024. The offering includes $1,150,000,000 of 4.800% notes due 2029, $1,150,000,000 of 4.900% notes due 2031, $850,000,000 of 4.950% notes due 2034, and $850,000,000 of 5.250% notes due 2054. The notes are senior unsecured obligations and will rank equally with other unsecured and unsubordinated debt. The company may redeem the notes at any time at specified redemption prices. The proceeds are intended for general corporate purposes, including the recently announced acquisition of Shockwave Medical, Inc., subject to customary closing conditions and regulatory approvals. The notes will be delivered through The Depository Trust Company on May 20, 2024, with J.P. Morgan, BofA Securities, and Citigroup acting as Joint Book-Running Managers.
领先的医疗保健公司强生公司（JNJ.US）宣布发行一系列总额为40亿美元的优先无抵押票据，期限和利率各不相同。这些票据将于2029年、2031年、2034年和2054年到期，将从2024年12月1日起每半年支付利息。此次发行包括2029年到期的1.15亿美元4.800％票据、1.15亿美元2031年到期的4.900％票据、2034年到期的8.5亿美元4.950％票据以及2054年到期的8.5亿美元5.250％票据。这些票据是优先无抵押债务，将与其他无抵押和非次级债务同等排名。公司可以随时以指定的赎回价格兑换票据。所得款项将用于一般公司用途，包括最近宣布的对Shockwave Medical, Inc. 的收购，但须遵守惯例成交条件和监管部门的批准。这些票据将于2024年5月20日通过存托信托公司交付，摩根大通、美银证券和花旗集团将担任联席账面管理人。
领先的医疗保健公司强生公司（JNJ.US）宣布发行一系列总额为40亿美元的优先无抵押票据，期限和利率各不相同。这些票据将于2029年、2031年、2034年和2054年到期，将从2024年12月1日起每半年支付利息。此次发行包括2029年到期的1.15亿美元4.800％票据、1.15亿美元2031年到期的4.900％票据、2034年到期的8.5亿美元4.950％票据以及2054年到期的8.5亿美元5.250％票据。这些票据是优先无抵押债务，将与其他无抵押和非次级债务同等排名。公司可以随时以指定的赎回价格兑换票据。所得款项将用于一般公司用途，包括最近宣布的对Shockwave Medical, Inc. 的收购，但须遵守惯例成交条件和监管部门的批准。这些票据将于2024年5月20日通过存托信托公司交付，摩根大通、美银证券和花旗集团将担任联席账面管理人。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息